Erythrocyte-active agents and treatment of sickle cell disease

Seminars in Hematology

Volumn 38, Issue 4, 2001, Pages 324-332

  Brugnara, Carlo ^a   De Franceschi, Lucia ^a,b,c   Beuzard, Yves ^a,b,c  

^a BOSTON CHILDREN S HOSPITAL   (United States)

^b UNIVERSITY OF VERONA   (Italy)

^c Service Oncologie et Hématologie Hôpital Louis Pasteur   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLCYSTEINE; ALLOPURINOL; ANTIOXIDANT; ARGINYLGLYCYLASPARTIC ACID; ASCORBIC ACID; CD36 ANTIGEN; CETIEDIL CITRATE; CLOTRIMAZOLE; COLLAGEN; HEMOGLOBIN A; HEMOGLOBIN F; HEMOGLOBIN S; HYDROXYUREA; ICA 17403; ILOPROST; INTEGRIN RECEPTOR; INTERCELLULAR ADHESION MOLECULE 1; NITRIC OXIDE; NS 1652; NS 3623; PENTOXIFYLLINE; POLOXAMER; POLYMERIZED HEMOGLOBIN; POTASSIUM CHANNEL; POTASSIUM CHANNEL BLOCKING AGENT; PYROGLUTAMATE MAGNESIUM; SURFACTANT; THROMBOSPONDIN; TUCARESOL; UNCLASSIFIED DRUG; VELARESOL;

BLOOD RHEOLOGY; CELL ADHESION; CHLORIDE TRANSPORT; DEHYDRATION; DRUG MECHANISM; ENDOTHELIUM CELL; ERYTHROCYTE MEMBRANE; HUMAN; HYPERBARIC OXYGEN; NONHUMAN; PRIORITY JOURNAL; REVIEW; SICKLE CELL ANEMIA; SODIUM TRANSPORT; TRANSGENIC MOUSE; VEIN OCCLUSION;

EID: 0034778646     PISSN: 00371963     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0037-1963(01)90026-5     Document Type: Article

References (118)

1. Vanillin, a potential agent for the treatment of sickle cell anemia
2. How allosteric effectors can bind to the same protein residue and produce opposite shifts in the allosteric equilibrium
3. Modification of sickle hemoglobin by acetaldehyde and its effect on oxygenation, gelation and sickling
4. Reactivity of the amino groups of carbonmonoxy HbS to glyceraldehyde
5. RheothRx (Poloxamer 188) injection for the acute painful episode of sickle cell disease: A pilot study
6. + channels by cytochrome P-450 inhibitors
7. Covalent binding of poly(ethylene glycol) (PEG) to the surface of red blood cells inhibits aggregation and reduces low shear blood viscosity
8. Tucaresol increases oxygen affinity and reduces haemolysis in subjects with sickle cell anaemia
9. Preliminary studies of continuous extracorporeal carbamylation in the treatment of sickle cell anemia
10. Anionic polysaccharides inhibit adhesion of sickle erythrocytes to the vascular endothelium and result in improved hemodynamic behavior
11. 5′-Deoxypyridoxal as a potential anti-sickling agent
12. A collaborative, double-blind randomized study of cetidiel citrate in sickle cell crisis
13. The feasibility of pharmacological volume control of sickle cells is dependent on the quantization of the transport pathways. A model study
14. Specific blockers of chloride conductance, NS1652 and NS3623, reduce sickle cell dehydration in vitro and in vivo
15. Treatment with NS3623, a novel Cl-conductance blocker, ameliorates erythrocyte dehydration in transgenic SAD mice: A possible new therapeutic approach for sickle cell disease
16. Volume control in sickle cells is facilitated by the novel anion conductance inhibitor NS 1652
17. Effect of cetidiel, an in vitro antisickling agent, on erythrocyte membrane cation permeability
18. The effect of methemoglobin formation in sickle cell disease
19. Is magnesium content in erythrocytes suitable for evaluating cation retention after oral physiological supplementation in marginally magnesium-deficient subjects?
20. A multiparameter analysis of sickle erythrocytes in patients undergoing hydroxyurea therapy
21. The molecular pathobiology of cell membrane iron: The sickle red cell as a model
22. Red cell membrane in sickle cell disease
23. + channel: The imidazole ring is not required for inhibitory activity
24. Regulation of erythrocyte cation and water content in sickle cell anemia
25. + transport in erythrocytes. Comparison of binding and transport inhibition by scorpion toxins
26. + transport and cell dehydration in sickle erythrocytes by clotrimazole and other imidazole derivatives
27. Therapy with oral clotrimazole induces inhibition of the Gardos channel and reduction of erythrocyte dehydration in patients with sickle cell disease
28. Regulation of cation content and cell volume in erythrocytes from patients with homozygous hemoglobin C disease
29. Inhibition of K transport by divalent cations in sickle erythrocytes
30. Acid pH induces formation of dense cells in sickle erythrocytes
31. Pathogenesis and treatment of sickle cell disease
32. Potassium cyanate as an inhibitor of the sickling of erythrocytes in vitro
33. Inhibition of sickling by methyacetimidate
34. Effect of hydroxyurea on the frequency of painful crises in sickle cell anemia
35. Failure of desmopressin to lower serum sodium or prevent crisis in patients with sickle cell anemia
36. Mechanism for the increase in solubility of deoxyhemoglobin S due to cross-linking the beta chains between lysine-82 beta 1 and lysine-82 beta 2
37. Convergence of Schiff base costimulatory signaling and TCR signaling at the level of mitogen-activated protein kinase ERK 2
38. Schiff base forming drugs: Mechanisms of immune potentiation and therapeutic potential
39. Vitamin C deficiency in patients with sickle cell anemia
40. Treatment of sickle cell crisis with urea in invert sugar - A controlled trial
41. Sickle-cell anemia: Molecular and cellular bases of therapeutic approaches
42. Hematologic and clinical responses in patients with sickle cell anemia after chronic extracorporeal red cell carbamylation
43. Oral magnesium supplements reduce erythrocyte dehydration in patients with sickle cell disease
44. Oral magnesium pidolate: Effects of long-term administration in patients with sickle cell disease
45. Modulation of erythrocyte potassium chloride cotransport, potassium content, and density by dietary magnesium intake in transgenic SAD mouse
46. + transport and reverses erythrocyte dehydration in transgenic SAD mice. A model for therapy of sickle cell disease
47. Sickle cell hemoglobin polymerization
48. Mechanisms of stroke in sickle cell disease: Sickle erythrocytes decrease cerebral blood flow in rats after nitric oxide synthase inhibition
49. The alkylation of HbS by nitrogen mustard
50. The function of calcium in the potassium permeability of human erythrocytes
51. Binding of 21 thiol reagents to human hemoglobin in solution and in intact cells
52. The efficacy of reducing agents or antioxidants in blocking the formation of dense cells and irreversibly sickled cells in vitro
53. Sodium cyanate as a potential treatment for sickle-cell disease
54. Cation permeability alteration during sickling: Relationship to cation composition and cellular dehydration of irreversibly sickled cells
55. Relative role of heme nitrosylation and beta-cysteine 93 nitrosation in the transport and metabolism of nitric oxide by hemoglobin in the human circulation
56. Inhaled nitric oxide augments nitric oxide transport on sickle cell hemoglobin without affecting oxygen affinity
57. Low concentrations of nitric oxide increase oxygen affinity of sickle erythrocytes in vitro and in vivo
58. The sickle erythrocyte in double jeopardy: Autoxidation and iron decompartmentalization
59. Increased adhesion of erythrocytes to components of the extracellular matrix: Isolation and characterization of a red blood cell lipid that binds thrombospondin and laminin
60. Hydroxyurea therapy decreases the in vitro adhesion of sickle erythrocytes to thrombospondin and laminin
61. Effect of nitric oxide and nitric oxide donors on red blood cell oxygen transport
62. Nitric oxide-mediated heme oxidation and selective beta-globin nitrosation of hemoglobin from normal and sickle erythrocytes
63. In vivo production of nitric oxide in rats after administration of hydroxyurea
64. Deoxygenation-induced cation fluxes in sickle cells: II. Inhibition by stilbene disulfonates
65. Cation transport and volume regulation in sickle red blood cells
66. Dipyridamole inhibits in vitro deoxygenation-induced cation fluxes in sickle red blood cells at the membrane concentration achievable in blood
67. Deoxygenation-induced cation fluxes in sickle cells: Relationship between net potassium efflux and net sodium influx
68. Deoxygenation-induced cation fluxes in sickle cells. IV. Modulation by external calcium
69. Deoxygenation-induced cation fluxes in sickle cells. III. Cation selectivity and response to pH and membrane potential
70. Cation depletion by the sodium pump in red cells with pathologic cation leaks. Sickle cells and xerocytes
71. Pharmacological modification of oxygen affinity improves deformability of deoxygenated sickle erythrocytes: A possible therapeutic approach to sickle cell disease
72. Inhibition of plasma-mediated adherence of sickle erythrocytes to microvascular endothelium by conformationally constrained RGD-peptides
73. Antioxidants in sickle cell disease: The in vitro effects of ascorbic acid
74. Platelet glycoprotein IIb/IIIa receptors in cardiovascular medicine
75. Compartmentalization of sickle-cell calcium in endocytic inside-out vesicles
76. 2+ permeability
77. Nitric oxide metabolite levels in acute vaso-occlusive sickle-cell crisis
78. Sequential nitric oxide measurements during the emergency department treatment of acute vaso-occlusive sickle cell crisis
79. Irreversible deformation of the spectrin-actin lattice in irreversibly sickled cells
80. Potential therapeutic applications of fructose-1, 6-diphosphate
81. Flocor (purified Poloxamer 188) may prevent acute chest syndrome in sickle cell disease patients
82. Patterns of 1-arginine and nitric oxide production in SCD children hospitalized with vaso-occlusive crisis and acute chest syndrome
83. Arginine therapy: A new treatment for pulmonary hypertension in sickle cell disease?
84. Cytosolic free calcium in sickle red blood cells
85. Molecular mechanism of red cell "sickling."
86. Oral L-glutamine therapy for sickle cell anemia: I. Subjective clinical improvement and favorable change in red cell NAD redox potential
87. Intracellular polymerization. Disease severity and therapeutic predictions
88. Inhibition of the in vitro formation of irreversibly sickled cells by cepharanthine
89. Nitrendipine, nifedipine and verapamil inhibit the in vitro formation of irreversibly sickled cells
90. The mechanism of in vitro formation of irreversibly sickled cells and modes of action of its inhibitors
91. Inhibition of the in vitro formation of dense cells and of irreversibly sickled cells by charybdotoxin, a specific inhibitor of calcium-activated potassium efflux
92. Oxidative damage and erythrocyte membrane transport abnormalities in thalassemias
93. Deoxygenation permeabilizes sickle cell anaemia red cells to magnesium and reverses its gradient in the dense cells
94. Erythrocyte and plasma magnesium in sickle-cell anaemia
95. Changes in glucose turnover parameters and improvement of glucose oxidation after 4 week magnesium administration in elderly noninsulin-dependent (type II) diabetic patients
96. A phase I study of the left-shifting agent BW 12C79 plus mitomycin C and the effect on the skeletal muscle metabolism using 31P magnetic resonance spectroscopy
97. Intracellular hemoglobin S polymerization and the clinical severity of sickle cell anemia
98. Depressant effect of high concentrations of inspired oxygen on erythrogenesis observations on patients with sickle cell anemia with a description of the observed toxic manifestations of oxygen
99. Nonrandom association of free iron with membranes of sickle and beta-thalassemic erythrocytes
100. Therapeutic potentiation of the immune system by costimulatory Schiff-base-forming drugs
101. HPLC measurement, blood distribution, and pharmacokinetics of oral clotrimazole, potentially useful antisickling agent
102. A phase 1 safety, pharmacokinetic, and pharmacodynamic study of ascending, single, oral doses of ICA-17043, a novel Gardos channel inhibitor for the treatment of sickle cell disease
103. 2+ permeability in deoxygenated sickle cells
104. A study of induced hyponatremia in the prevention and treatment of sickle-cell crisis
105. Chemical camouflage of antigenic determinants: Stealth erythrocytes
106. Specific modification of the carboxyl groups of hemoglobin S
107. Peroxidative damage in sickle-cell erythrocyte ghosts: Protective effect of allopurinol
108. Deferiprone (L1) chelates pathologic iron deposits from membranes of intact thalassemic and sickle red blood cells both in vitro and in vivo
109. The use of carbon monoxide on red cell life span in sickle cell disease
110. A novel Gardos channel inhibitor, ICA-17043, prevents red blood cell dehydration in vitro and in a mouse model (SAD) of sickle cell disease
111. Decrease of very late activation antigen- 4 and CD36 on reticulocytes in sickle cell patients treated with hydroxyurea
112. Potassium and sodium of red blood cells in sickle cell anemia
113. Sickle cell disease of transgenic SAD mice
114. Basal cell adhesion molecule/lutheran protein. The receptor critical for sickle cell adhesion to laminin
115. Thiol compounds as protective agents in erythrocytes under oxidative stress
116. X-ray diffraction study of the binding of the antisickling agent 12C79 to human hemoglobin
117. Crystal structure of sickle-cell deoxyhemoglobin at 5 A resolution
118. Schiff base adducts of hemoglobin. Modifications that inhibit erythrocyte sickling